The efficacy of topical solution of 0.3% ciprofloxacin in treatment of mild to moderate acne vulgaris

Iranian Red Crescent Medical Journal

Volumn 11, Issue 1, 2009, Pages 23-27

  Vali, Anahita ^a,b   Faghihi, G ^b   Zaghian, N ^b   Koosha, M ^b  

^a Iranian Hospital Dubai   (United Arab Emirates)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acne vulgaris; Ciprofloxacin; Therapy; Topical

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; ERYTHROMYCIN;

ACNE VULGARIS; ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMEDO; CONCURRENT INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PAPULE; PUSTULE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SINGLE BLIND PROCEDURE; SKIN IRRITATION; XEROSIS;

EID: 67649395764     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Tan HH. Antibacterial Therapy for Acne: A Guide to Selection and Use of Systemic Agents. Am J Clin Dermatol 2003;4 (5):307-14. [12688836] [doi:10.2165/00128071-200304050-00002]
2. Sweetman SC. Martindale Complete Drug Reference. 33th ed., PhP Press. London, 2002; pp. 182-3, 1103.
3. Breathnach SM, Griffiths CEM, Chalmers RJG, Hay RJ. Systemic therapy. Burns T, Breathnach S, Cox N & Griffiths C. In: Rooks Textbook of Dermatology. 7th ed., Blackwell Science, USA, 2004; pp. 72.33-34, 73.62.
4. Wyatt EL, Sutter SH, Drake LA. Dermatological Pharmacology. In: Hardman JG, Limbird LE. Goodman and Gillmans Pharmacologic Basis of Therapeutics. 10th ed., Mc Grawhill Co., New york, 2002; pp. 1809-1810.
5. Cunliffe W, Gollnick H. Acne. In: Arndt KA, Leboit PE, Robinson JK, Wintroub BU. Cutaneous Medicine and Surgery. First ed., Saunders Co., USA, 1996; pp. 468-473.
6. Hooper DC. Quinolones. In: Mandell Gl, Bennett JE, Dolin R. Principles and practice of infectious diseasea. 6th ed., Churchill Livingstone Co., Philadelphia, 2005; pp. 451-467.
7. Sayoko E, Mand Paul RL. Ocular Pharmacology. Hardman JG, Limbird LE. Goodman and Gillmans Pharmacologic Basis of Therapeutics. 10th ed., Mc Grawhill Co., 2002; pp. 1830-31.
8. Resh W, Stoughton RB. Topically applied antibiotics in acne vulgaris: clinical response and suppression of corynebacterium acnes in open comedones. Arch Dermatol 1976;112 (2):182-4. [134675] [doi:10.1001/archderm.112.2.182]
9. Bernstein JE, Shalita AR. Topically applied erythromycin in inflammatory acne vulgaris. J Am Acad Dermatol 1980;2(4):318-21. [6444958]
10. Krautheim A, Gollnick HP. Acne: Topical treatment. Clin Dermatol 2004;22(5):398-407. [15556726] [doi:10.1016/ j.clindermatol.2004.03.009]
11. Fass RJ. Treatment of skin and softtissue infections with oral ciprofloxacin. J Antimicrob Chemother 1986; 18:153-7. [3804903] [doi:10.1093/jac/18.2.153]
12. Kimyai-Asadi A, Usman A, Nousari HC. Ciprofloxacin induced bollous pemphygoid. J Am Acad Dermatol 2000;42 (5):847. [10775871]
13. Vogt K, Hermann J, Blume U, Gollnick H, Hahn H, Haustein UF, Orfanos CE. Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris. Eur J Clin Microbiol Infect Dis 1992;11(10):943-5. [1486893] [doi:10.1007/BF01962381]
14. Langner A, Sheehan-Dare R, Layton A. A randomized, singleblind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. J Eur Acad Dermatol Venereol 2007; 21(3):311-9. [17309451] [doi:10.1111/j.1468-3083.2006.01884.x]